Researchers engineer pancreatic cell transplants to evade immune response
SEIU healthcare members began casting ballots this week in an advisory vote on two reorganization plans. Members will have an opportunity to register their preferences on whether they want to be part of a new single statewide long-term care local union or a new statewide local representing a broader classification of healthcare workers. “The SEIU
Full Post: Advisory vote begins on California long-term care local union
In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients.
At present, cell transplantation therapy is limited because transplant recipients are forced to take powerful immunosuppressant medications that have toxic side effects and raise the risk of infection. This advance in mice, described in the online version of Gene Therapy , could pave the way for routine use of cell transplants as a therapy for type 1 diabetes in humans.
Type 1 diabetes is an incurable autoimmune disease in which the immune system mistakenly destroys the body’s own pancreatic beta cells. Beta cells produce insulin, which breaks down sugar, or glucose, for use by the body. Without these cells, too much glucose builds up in the blood. High blood glucose levels damage cells and can eventually lead to complications such as heart disease, kidney disease, blindness, and premature death.
Type 1 diabetes affects up to 2.4 million Americans and can develop at any age, though it typically appears during childhood or adolescence. People with type 1 diabetes must closely monitor their blood glucose levels and take daily insulin injections for life.
A promising alternative to insulin injections is cellular transplantation, in which beta cells are harvested from cadavers and injected into the bloodstream of patients with diabetes; the new cells replace the recipients’ destroyed pancreatic beta cells. Although such transplants can control type 1 diabetes, recipients must take immunosuppressant medications in order to prevent rejection of these beta foreign cells. “Ultimately, even with immunosuppressive therapy, most of these individuals end up rejecting the transplanted cells,” says the study’s principal investigator, Harris Goldstein, M.D., professor of pediatrics and of microbiology & immunology at Einstein.
In this study, Dr. Goldstein and his colleagues devised a way to make foreign beta cells invisible to a transplant recipient’s immune system, dramatically protecting them from rejection. They did so by harnessing the innate ability of adenoviruses to evade the body’s immune surveillance system. (Adenoviruses infect tissues that line the respiratory tract, eyes, intestines, and urinary tract). After infecting cells, adenoviruses produce proteins that prevent the cells from signaling the immune system that they have been infected and should be destroyed. The viruses also produce proteins that can turn off a cell’s built-in self-destruct mechanism, which is usually triggered when something disturbs a cell’s internal functions.
The researchers began with a special line of insulin-producing beta cells, developed at Einstein, that were harvested from mice. When injected into diabetic mice, these foreign cells can restore normal glucose control, but only temporarily. The transplanted cells are soon destroyed by the mouse’s immune system and glucose levels begin to rise, returning to pre-transplant disease levels.
Dr. Goldstein and his colleagues genetically engineered these beta cells to include three adenoviral genes responsible for making immunosuppressive proteins. Diabetic mice that received these engineered foreign beta cells maintained normal glucose control for up to three months. In contrast, a control group of diabetic mice that received the regular foreign beta cells exhibited normal glucose control for just a few days.
“Clearly, the three proteins were not optimal, because ultimately the cells did get rejected,” says Dr. Goldstein. “We are now looking at other viral genes that also contribute to immune suppression and are trying to identify the best gene combination to use.”
Dr. Goldstein views the current experiment as a proof of concept. “We were able to demonstrate that genetically engineered beta cells can be made highly resistant to rejection and can basically correct diabetes. This technique could conceivably be applied to protect any type of cellular transplant from rejection.”
However, pancreatic cell transplantation could not help treat patients with type 2 diabetes. In this form of the disease, patients have fully functional beta cells but cells throughout their body become resistant to insulin.
Researchers at the Joslin Diabetes Center have shown that insulin-producing pancreatic beta cells can form after birth or after injury from progenitor cells within the pancreas that were not beta cells, a finding that contradicts a widely-cited earlier study that had concluded this is not possible. The study, published online this week in the Proceedings
Full Post: Pancreatic duct cells identified as new source of insulin-producing cells
The body’s immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it. This is the problem when people with type 1 diabetes undergo human islet cell transplantation. The islet cells from a donor pancreas produce robust amounts of insulin for the recipient — often permitting independence from insulin therapy. However,
Full Post: Scientists trick immune system of mice into believing transplanted islets are its own cells
Singapore researchers have developed an unlimited number of pure insulin-producing cells from mouse embryonic stem cells (ESCs). These pure insulin-producing cells, which according to electron microscopy studies, have the same sub-cellular structures as the insulin-producing cells naturally found in the pancreas, were highly effective in treating diabetes in the mouse model. The transplants of pure
Full Post: Scientists develop unlimited pure insulin-producing cells from mouse embryonic stem cells
An important piece in the diabetes puzzle which has perplexed scientists for decades has been uncovered by a Sydney PhD student at Sydney’s Garvan Institute of Medical Research. The novel finding by Freddy Yip has revealed how insulin works and brings researchers one step nearer to understanding just how insulin prompts fat and muscle cells
Full Post: Sydney student solves piece of the diabetes puzzle
Type 1 (juvenile) diabetes and celiac disease appear to share a common genetic origin, scientists at the University of Cambridge and Barts and The London School of Medicine and Dentistry, have confirmed. Their findings, which are reported in this week’s edition of the New England Journal of Medicine, identified seven chromosome regions which are shared
Full Post: Genetic links found between type 1 diabetes and celiac disease